Scarica l'app Stockscreener
15.05
0.53%
-0.08
Dopo l'orario di chiusura:
15.11
0.06
+0.40%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$15.13
Aprire:
$15.13
Volume 24 ore:
49,138
Relative Volume:
0.44
Capitalizzazione di mercato:
$311.64M
Reddito:
$306.91M
Utile/perdita netta:
$-59.11M
Rapporto P/E:
-100.33
EPS:
-0.15
Flusso di cassa netto:
$6.35M
1 W Prestazione:
+0.53%
1M Prestazione:
-10.04%
6M Prestazione:
+31.65%
1 anno Prestazione:
+6.69%
Intervallo 1D:
$14.64
$15.20
Intervallo di 1 settimana:
$14.05
$15.65
Portata 52W:
$7.08
$17.49
Amarin Corp Adr Stock (AMRN) Company Profile
Nome
Amarin Corp Adr
Settore
Industria
Telefono
353 1 6699 020
Indirizzo
SPACES SOUTH DOCKLANDS, BLOCK C, DUBLIN 2
Confronta AMRN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
AMRN
Amarin Corp Adr
|
15.05 | 312.93M | 306.91M | -59.11M | 6.35M | -0.15 |
|
LLY
Lilly Eli Co
|
746.37 | 687.62B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
170.59 | 411.20B | 90.63B | 22.66B | 16.40B | 9.35 |
|
ABBV
Abbvie Inc
|
196.30 | 350.75B | 58.33B | 3.76B | 18.24B | 2.10 |
|
NVS
Novartis Ag Adr
|
113.50 | 227.91B | 55.19B | 13.65B | 16.81B | 6.86 |
|
MRK
Merck Co Inc
|
79.44 | 202.87B | 63.62B | 16.41B | 14.72B | 6.49 |
Amarin Corp Adr Stock (AMRN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2023-11-20 | Ripresa | JP Morgan | Underweight |
| 2023-10-25 | Downgrade | Jefferies | Buy → Hold |
| 2023-01-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-05-06 | Downgrade | JP Morgan | Neutral → Underweight |
| 2022-05-05 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2022-05-05 | Downgrade | SVB Leerink | Outperform → Mkt Perform |
| 2022-05-04 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2021-05-12 | Downgrade | Goldman | Neutral → Sell |
| 2020-09-29 | Ripresa | JP Morgan | Neutral |
| 2020-08-26 | Iniziato | Piper Sandler | Overweight |
| 2020-05-05 | Iniziato | Northland Capital | Outperform |
| 2020-03-31 | Downgrade | Goldman | Buy → Neutral |
| 2020-03-31 | Downgrade | Jefferies | Buy → Hold |
| 2020-03-31 | Aggiornamento | Oppenheimer | Underperform → Perform |
| 2020-03-13 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-02 | Iniziato | Cowen | Outperform |
| 2020-02-18 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-01-06 | Iniziato | JP Morgan | Neutral |
| 2019-12-16 | Downgrade | Stifel | Buy → Hold |
| 2019-11-20 | Iniziato | Oppenheimer | Underperform |
| 2019-11-18 | Downgrade | Citigroup | Buy → Neutral |
| 2019-11-15 | Reiterato | SVB Leerink | Outperform |
| 2019-10-31 | Iniziato | Aegis Capital | Buy |
| 2019-10-15 | Iniziato | Goldman | Neutral |
| 2019-08-14 | Iniziato | SVB Leerink | Outperform |
| 2019-07-09 | Reiterato | Jefferies | Buy |
| 2019-06-17 | Iniziato | ROTH Capital | Buy |
| 2019-03-22 | Iniziato | Stifel | Buy |
Mostra tutto
Amarin Corp Adr Borsa (AMRN) Ultime notizie
Amarin's Q2 Earnings & Revenues Trump Estimates, Stock Rises - Barchart.com
Amarin Gears Up To Report Q2 Earnings: Here's What To Expect - Barchart.com
VKTX Stock Down On Wider-Than-Expected Loss In Q2, Nil Sales - Barchart.com
Zacks.com featured highlights include Mama's Creations, Bassett Furniture Industries and Amarin - Barchart.com
KRYS Begins Dosing With Gene Therapy In Rare Eye Disease, Stock Up - Barchart.com
RYTM Stock Rises On Upbeat Acquired Hypothalamic Obesity Study Data - Barchart.com
PROK Surges More Than 500% On Upbeat Data From Kidney Cell Therapy Study - Barchart.com
Amarin Soars 27% on Vazkepa Licensing Deal With Recordati in the EU - Yahoo Finance
Amarin licenses VAZKEPA to Recordati in 59 European countries - Investing.com
Is Amarin (AMRN) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
KURA Stock Rises More Than 15% This Past Week: Here's Why - Barchart.com
Is GSK PLC Sponsored ADR (GSK) Outperforming Other Medical Stocks This Year? - Yahoo Finance
RCKT Stock Tanks On Patient Death In Danon Disease Study - Barchart.com
SpringWorks Gets CHMP Nod For Mirdametinib In Rare Disease - Barchart.com
Amarin's Q1 Earnings Beat Estimates, Revenues Decline Y/Y - Barchart.com
Amarin earnings beat by $0.04, revenue topped estimates - Investing.com
Amarin to Report First Quarter 2025 Financial Results and Host Conference Call on May 7, 2025 - Barchart.com
Press Release Distribution & PR Platform - ACCESS Newswire
Looking For A Top Momentum Stock? Check Out Amarin Corp ADR (NASDAQ: AMRN) - Stocksregister
Amarin Takes Critical Step to Avoid Nasdaq Delisting with 1-for-20 Share Consolidation - Stock Titan
Amarin announces ADS ratio change to meet Nasdaq requirements - Investing.com
Major Shake-up: Investment Firm Leader Joins Amarin Board to Drive Shareholder Value - Stock Titan
Amarin adds investment expert Michael Torok to Board By Investing.com - Investing.com
Upcoming Stock Splits This Week (April 7 to April 11) – Stay Invested - markets.businessinsider.com
A Look at New Gold Inc (NGD) Shares in the Recent Past Indicates Growth - Sete News
Breakthrough: EPA Treatment Shows Double Impact on Heart Disease When Combined with Popular Diabetes Drug - Stock Titan
Amarin announces board member departure ahead of annual meeting - Investing.com
European Equities Traded in the US as American Depositary Receipts Higher in Monday Trading - TradingView
European Equities Traded in the US as American Depositary Receipts Track Lower in Wednesday Trading - TradingView
Amarin urged to review strategy by major shareholders - Investing.com
Assessing the Risk and Potential of Sempra’s (SRE) Stock - The News Heater
Amarin Corporation plc (NASDAQ:AMRN) Q4 2024 Earnings Call Transcript - Insider Monkey
Amarin Corp PLC (AMRN) Q4 2024 Earnings Call Highlights: Navigating Challenges and Expanding ... - Yahoo Finance
Amarin Plc (AMRN) Q4 2024 Earnings Call Transcript - The Motley Fool
Amarin announce splan to initiate ratio change under ADR program - TipRanks
Amarin Announces Plan to Initiate a Ratio Change Under Its American Depository Receipt (ADR) Program - The Manila Times
Amarin Corp. (AMRN) Announces 1-For-20 ADS Ratio Change to Maintain Nasdaq Listing - StreetInsider.com
Amarin Plans Major ADR Restructuring: What This 1:20 Ratio Change Means for Investors - StockTitan
Amarin Announces 1-for-20 Reverse Stock Split - TipRanks
How Amarin's Latest European Reimbursement Victory Strengthens Its Cardiovascular Market Position - Stock Titan
Will Amarin's Q4 Earnings Mark a Turning Point? Key Date and Details Revealed - Stock Titan
Amarin Corp ADR (AMRN) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - SETE News
European Equities Traded in the US as American Depositary Receipts Tread Water in Wednesday Trading - TradingView
Amarin Corp ADR [AMRN] Stock bought by Insider Berg Aaron for $0.1 million - Knox Daily
Ratios Uncovered: Breaking Down Amarin Corp ADR (AMRN)’s Trailing Twelve Months Metrics - The Dwinnex
Checking in on Indivior Plc (INDV) after recent insiders movement - Knox Daily
Ratios Uncovered: Breaking Down Neuronetics Inc (STIM)’s Trailing Twelve Months Metrics - The Dwinnex
Are Smart Investors Making the Right Decision? Amarin Corp ADR (AMRN) - SETE News
Amarin Corp ADR (AMRN) shows promising results - US Post News
Amarin stock touches 52-week low at $0.45 amid challenges - Investing.com
Italy grants VAZKEPA reimbursement for heart risk - Investing.com
Amarin Corp Adr Azioni (AMRN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):